Biomarin Pharmaceutical (BMRN) Other Gross PP&E Adjustments (2016 - 2025)
Historic Other Gross PP&E Adjustments for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $2.0 billion.
- Biomarin Pharmaceutical's Other Gross PP&E Adjustments rose 382.46% to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year increase of 382.46%. This contributed to the annual value of $1.9 billion for FY2024, which is 118.34% up from last year.
- According to the latest figures from Q3 2025, Biomarin Pharmaceutical's Other Gross PP&E Adjustments is $2.0 billion, which was up 382.46% from $2.0 billion recorded in Q2 2025.
- In the past 5 years, Biomarin Pharmaceutical's Other Gross PP&E Adjustments ranged from a high of $2.0 billion in Q3 2025 and a low of $1.7 billion during Q4 2021
- In the last 5 years, Biomarin Pharmaceutical's Other Gross PP&E Adjustments had a median value of $1.9 billion in 2024 and averaged $1.8 billion.
- As far as peak fluctuations go, Biomarin Pharmaceutical's Other Gross PP&E Adjustments surged by 972.69% in 2021, and later crashed by 39.18% in 2025.
- Over the past 5 years, Biomarin Pharmaceutical's Other Gross PP&E Adjustments (Quarter) stood at $1.7 billion in 2021, then grew by 7.45% to $1.8 billion in 2022, then grew by 2.83% to $1.8 billion in 2023, then increased by 1.18% to $1.9 billion in 2024, then rose by 6.67% to $2.0 billion in 2025.
- Its Other Gross PP&E Adjustments stands at $2.0 billion for Q3 2025, versus $2.0 billion for Q2 2025 and $1.9 billion for Q1 2025.